Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mani

Showing results (101-110 of 169) with videos related to

Pageof 17
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Gastroenterology|January 30, 2018
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide AnaloguesCarolina Boni, Andrea Vecchi, Marzia Rossi, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.
Journal of Hepatology|August 24, 2024
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASHYasmine J Liu, Masaki Kimura, Xiaoxu Li, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Nature Medicine|January 16, 2026
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trialXiaoxu Li, Giorgia Benegiamo, Archana Vijayakumar, et al.
Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.
Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.
Pageof 17

Showing results (101-110 of 169) with videos related to

Sort By:
Pageof 17
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing CholangitisPalak J Trivedi, Andrew J Muir, Cynthia Levy, et al.
Gastroenterology|January 30, 2018
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide AnaloguesCarolina Boni, Andrea Vecchi, Marzia Rossi, et al.
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.
Journal of Hepatology|August 24, 2024
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASHYasmine J Liu, Masaki Kimura, Xiaoxu Li, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 20, 2019
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic SteatohepatitisZobair M Younossi, Maria Stepanova, Quentin M Anstee, et al.
Journal of Hepatology|May 24, 2016
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BAnna S Lok, Calvin Q Pan, Steven-Huy B Han, et al.
Nature Medicine|January 16, 2026
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trialXiaoxu Li, Giorgia Benegiamo, Archana Vijayakumar, et al.
Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.
Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.
Pageof 17